Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials
两项全球性、随机、3期临床试验评估了巴比妥单抗治疗轻度至中度阿尔茨海默病的疗效。
期刊:Alzheimers Research & Therapy
影响因子:7.6
doi:10.1186/s13195-016-0189-7
Vandenberghe, Rik; Rinne, Juha O; Boada, Mercè; Katayama, Sadao; Scheltens, Philip; Vellas, Bruno; Tuchman, Michael; Gass, Achim; Fiebach, Jochen B; Hill, Derek; Lobello, Kasia; Li, David; McRae, Tom; Lucas, Prisca; Evans, Iona; Booth, Kevin; Luscan, Gerald; Wyman, Bradley T; Hua, Lisa; Yang, Lingfeng; Brashear, H Robert; Black, Ronald S
